Non-alcoholic fatty liver disease (NAFLD) affects approximately one in three UK adults, yet many remain unaware of the crucial distinction between simple fatty liver and its more serious form, non-alcoholic steatohepatitis (NASH). Whilst simple fatty liver involves fat accumulation alone and rarely progresses, NASH combines steatosis with inflammation and liver cell damage, potentially leading to cirrhosis and liver failure. Understanding the difference between NASH and fatty liver is essential for appropriate risk assessment, monitoring, and management. This article explains the key differences, diagnostic approaches, and evidence-based treatment strategies to help you protect your liver health.
Summary: The key difference between NASH and fatty liver is that NASH involves hepatic steatosis plus inflammation and liver cell damage, whilst simple fatty liver involves only fat accumulation without significant inflammation or cellular injury.
- Simple fatty liver (NAFL) is characterised by fat accumulation in more than 5% of liver cells with minimal inflammation and low risk of progression to advanced liver disease.
- NASH (non-alcoholic steatohepatitis) combines fat accumulation with significant inflammation, hepatocellular injury, and potential for progressive fibrosis leading to cirrhosis.
- Approximately 10–20% of people with simple fatty liver may progress to NASH, and 10–20% of those with NASH may develop cirrhosis over 10–20 years.
- Standard blood tests and imaging cannot reliably distinguish NASH from simple fatty liver; validated fibrosis scores (FIB-4, ELF test) or liver biopsy may be required.
- Weight loss of 7–10% can significantly reduce hepatic steatosis, whilst loss exceeding 10% may resolve NASH and improve fibrosis in many patients.
- NICE recommends FIB-4 scoring in primary care for fibrosis risk stratification, with specialist referral for high-risk or indeterminate scores or ELF scores of 10.51 or above.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Fatty Liver Disease?
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. In healthy individuals, the liver contains minimal fat—typically less than 5% of its weight. When fat accumulates in more than 5% of hepatocytes (liver cells), the condition is classified as fatty liver disease.
There are two main categories of fatty liver disease: alcohol-related liver disease (ARLD), caused by excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD), which develops in people who drink little to no alcohol. NAFLD has become increasingly common in the UK, affecting approximately one in three adults to some degree. It is strongly associated with metabolic conditions including obesity, type 2 diabetes, high cholesterol, and hypertension.
Recent international guidance has introduced the term metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD, reflecting the central role of metabolic dysfunction. Whilst UK guidance from NICE and the NHS currently uses NAFLD terminology, you may encounter MASLD in newer literature. Both terms describe the same condition.
Simple fatty liver (also called non-alcoholic fatty liver or NAFL) represents the mildest form of NAFLD. At this stage, fat accumulates in the liver but causes minimal inflammation or cellular damage. Many people with simple fatty liver experience no symptoms and may remain unaware of the condition unless detected incidentally during imaging for other reasons. However, even simple fatty liver is associated with increased cardiovascular risk, making management of metabolic risk factors important.
The liver possesses remarkable regenerative capacity, and in cases of simple fatty liver, lifestyle modifications—particularly weight loss, improved diet, and increased physical activity—can often reverse fat accumulation. However, without intervention, approximately 10–20% of individuals may progress to more serious forms of liver disease, making early identification and management essential for long-term liver health.
What Is NASH (Non-Alcoholic Steatohepatitis)?
Non-alcoholic steatohepatitis (NASH) represents a more severe and progressive form of non-alcoholic fatty liver disease. In newer terminology, NASH is also called metabolic dysfunction-associated steatohepatitis (MASH), though UK guidance currently uses the NASH term. Whilst simple fatty liver involves fat accumulation alone, NASH is characterised by the combination of hepatic steatosis, inflammation, and hepatocellular injury (damage to liver cells). This inflammatory process can lead to fibrosis—the formation of scar tissue within the liver—which may ultimately progress to cirrhosis and liver failure if left unmanaged.
The pathophysiology of NASH involves a complex interplay of metabolic dysfunction, oxidative stress, and inflammatory pathways. Insulin resistance plays a central role, promoting fat accumulation in hepatocytes whilst simultaneously triggering inflammatory cascades. Lipotoxicity—cellular damage caused by excess lipids—leads to hepatocyte ballooning, apoptosis (programmed cell death), and the recruitment of immune cells that perpetuate inflammation. Over time, activated hepatic stellate cells deposit collagen, resulting in progressive fibrosis. Importantly, the stage of fibrosis is the strongest predictor of liver-related outcomes and mortality in NASH.
NASH affects approximately 2–5% of the UK population, though prevalence is considerably higher among individuals with obesity or type 2 diabetes. The condition typically develops insidiously over years or decades. Whilst many patients with NASH remain asymptomatic in early stages, the disease carries significant long-term risks. Studies suggest that 10–20% of people with NASH will develop cirrhosis over 10–20 years, and cirrhotic NASH substantially increases the risk of hepatocellular carcinoma (liver cancer) and liver-related mortality.
Currently, there is no licensed pharmacological treatment specifically for NASH in the UK, though several agents are under investigation in clinical trials. Management focuses primarily on addressing underlying metabolic risk factors and preventing disease progression through lifestyle intervention and treatment of associated conditions.
Key Differences Between NASH and Fatty Liver
Understanding the distinction between simple fatty liver and NASH is crucial for appropriate risk stratification and management. The fundamental difference lies in the presence and extent of liver inflammation and cellular damage.
Simple fatty liver (NAFL) is characterised by:
-
Fat accumulation in more than 5% of hepatocytes
-
Minimal or no inflammation
-
Absence of hepatocyte ballooning or significant cellular injury
-
Generally stable condition with low risk of progression to advanced liver disease
-
Excellent prognosis with lifestyle modification, though cardiovascular risk remains elevated
NASH, by contrast, involves:
-
Hepatic steatosis plus significant inflammation
-
Evidence of hepatocellular injury (ballooning degeneration)
-
Potential for progressive fibrosis and cirrhosis
-
Increased risk of liver-related complications and mortality
-
May require more intensive monitoring and intervention
From a histological perspective—the gold standard for diagnosis—NASH demonstrates a characteristic pattern of steatosis, lobular inflammation, and hepatocyte ballooning. Fibrosis staging (F0–F4) provides crucial prognostic information, with advanced fibrosis (F3–F4) indicating substantial risk of progression to cirrhosis. Simple fatty liver, conversely, shows steatosis without these inflammatory or fibrotic features.
It is important to note that standard imaging and blood tests cannot reliably distinguish simple fatty liver from NASH. When the distinction affects management decisions, liver biopsy or validated non-invasive biomarkers may be needed. The stage of fibrosis—rather than simply the presence of NASH versus simple steatosis—is the key factor driving prognosis and determining the intensity of follow-up required.
The clinical significance of this distinction cannot be overstated. Whilst simple fatty liver rarely causes serious liver disease, NASH represents a potentially progressive condition requiring closer surveillance. Research indicates that approximately 10–20% of people with simple fatty liver will progress to NASH, but once NASH develops, the trajectory becomes less predictable. Factors associated with progression include older age, obesity, diabetes, and the presence of advanced fibrosis at diagnosis. This underscores the importance of accurate diagnosis and appropriate risk stratification for all patients with fatty liver disease.
Symptoms and Diagnosis of NASH vs Fatty Liver
Both simple fatty liver and NASH are frequently asymptomatic, particularly in early stages, which presents diagnostic challenges. Most cases are identified incidentally through abnormal liver function tests or imaging performed for unrelated reasons.
When symptoms do occur, they tend to be non-specific and may include:
-
Persistent fatigue or malaise
-
Vague right upper quadrant discomfort
-
General sense of being unwell
Advanced NASH with significant fibrosis or cirrhosis may present with complications such as jaundice, ascites (fluid accumulation in the abdomen), peripheral oedema, or signs of hepatic encephalopathy. However, these features typically indicate established cirrhosis rather than early-stage disease.
Diagnostic approach begins with clinical assessment and blood tests. Your doctor will take a detailed alcohol history (quantified in UK units per week) and review any medications that may affect the liver, such as amiodarone, methotrexate, or tamoxifen. Liver function tests may show elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST), though normal values do not exclude fatty liver disease or NASH. A comprehensive metabolic screen should assess HbA1c or fasting glucose and lipid profile. Importantly, other causes of liver disease—including viral hepatitis, autoimmune conditions, and haemochromatosis—must be excluded.
Risk stratification for fibrosis is a key step in primary care, following NICE guidance. Initial assessment uses validated scoring systems:
-
FIB-4 score (based on age, ALT, AST, and platelet count): In adults under 65 years, a score below 1.3 indicates low risk of advanced fibrosis; 1.3–2.67 is indeterminate; above 2.67 suggests high risk. For people aged 65 and over, a threshold below 2.0 indicates low risk, as FIB-4 increases with age.
-
NAFLD Fibrosis Score is an alternative validated tool using similar parameters.
Patients with low-risk scores can be managed in primary care with lifestyle intervention and repeat fibrosis assessment every three years (every two years in children and young people). Those with indeterminate or high-risk scores should proceed to further testing.
Enhanced Liver Fibrosis (ELF) test is recommended by NICE as a second-line assessment. An ELF score of 10.51 or above indicates a high likelihood of advanced fibrosis and warrants specialist hepatology referral. Transient elastography (FibroScan) provides an alternative non-invasive assessment of liver stiffness, which correlates with fibrosis stage.
Imaging plays a crucial role in initial assessment. Ultrasound can detect hepatic steatosis but cannot reliably distinguish simple fatty liver from NASH or quantify fibrosis. More advanced imaging techniques may be used in specialist settings.
Liver biopsy remains the definitive diagnostic test, providing histological confirmation of NASH and accurate fibrosis staging. However, given its invasive nature and associated risks, biopsy is typically reserved for cases where diagnosis is uncertain, when precise staging would alter management, or when other liver diseases need to be excluded. NICE guidance suggests considering biopsy in patients with indeterminate non-invasive test results or when clinical features suggest advanced liver disease despite reassuring non-invasive tests.
Treatment and Management Options
Management of both simple fatty liver and NASH centres on addressing underlying metabolic dysfunction and preventing disease progression. Whilst no medications are currently licensed specifically for NASH in the UK, evidence-based lifestyle interventions form the cornerstone of treatment.
Weight loss represents the most effective intervention for fatty liver disease. Studies demonstrate that losing 7–10% of body weight can significantly reduce hepatic steatosis, and weight loss exceeding 10% may resolve NASH and improve fibrosis in many patients. NICE recommends a structured weight management programme incorporating dietary modification and increased physical activity. For individuals meeting specific criteria—typically a BMI of 40 kg/m² or above, or 35–39.9 kg/m² with significant comorbidities such as type 2 diabetes—referral for bariatric surgery assessment may be considered. In some cases, surgery may be considered at BMI 30–34.9 kg/m² with recent-onset type 2 diabetes. (Note that lower BMI thresholds are used to assess metabolic risk in some ethnic groups, but surgical referral criteria remain as stated.) Bariatric surgery has shown substantial benefits for liver health in appropriate candidates.
Dietary modifications should focus on:
-
Reducing refined carbohydrates and added sugars
-
Limiting saturated fats whilst incorporating healthy fats (omega-3 fatty acids)
-
Increasing consumption of vegetables, fruits, and whole grains
-
Avoiding excessive fructose from sweetened beverages
-
Moderating portion sizes to achieve caloric deficit
The Mediterranean diet pattern has demonstrated particular benefit in reducing hepatic steatosis and improving metabolic parameters.
Physical activity provides benefits independent of weight loss. The UK Chief Medical Officers recommend at least 150 minutes of moderate-intensity aerobic exercise weekly (or 75 minutes of vigorous activity), combined with muscle-strengthening activities on two or more days per week. Both aerobic and resistance exercise have been shown to reduce liver fat content.
Alcohol intake should be kept within UK low-risk guidelines: no more than 14 units per week, spread over three or more days, with several alcohol-free days each week. For people with established liver disease or significant fibrosis, complete abstinence may be advisable—discuss this with your doctor.
Management of comorbidities is essential. Optimal control of type 2 diabetes, hypertension, and dyslipidaemia reduces cardiovascular risk—the leading cause of mortality in NAFLD patients. Metformin is used for glycaemic control in type 2 diabetes but does not directly treat NAFLD or improve liver histology. Statins are safe in fatty liver disease and should be used when indicated for cardiovascular risk reduction according to NICE lipid management guidance.
Pioglitazone and vitamin E have shown some benefit in biopsy-proven NASH in clinical trials, but their use for NASH is not licensed in the UK (off-label). These treatments should only be considered under specialist hepatology supervision, with careful patient selection and counselling about risks. Pioglitazone carries risks including weight gain, fluid retention (which may worsen heart failure), and increased fracture risk. Vitamin E has uncertainties regarding long-term safety. If you are prescribed either medication, your specialist will discuss the potential benefits and risks with you.
Vaccinations: People with chronic liver disease, including those with advanced fibrosis or cirrhosis, should be offered hepatitis A and hepatitis B vaccination to reduce the risk of additional liver injury.
Patients with advanced fibrosis or cirrhosis require specialist hepatology input and surveillance for complications including hepatocellular carcinoma and oesophageal varices.
Reporting side effects: If you experience side effects from any medication, you can report them via the MHRA Yellow Card Scheme at www.mhra.gov.uk/yellowcard or by searching for 'Yellow Card' in the Google Play or Apple App Store.
When to See a Doctor About Liver Health
Given the asymptomatic nature of early fatty liver disease and NASH, proactive engagement with healthcare services is important, particularly for individuals with metabolic risk factors.
You should arrange a routine GP appointment if you:
-
Have risk factors including obesity, type 2 diabetes, high cholesterol, hypertension, or metabolic syndrome
-
Have a family history of liver disease
-
Have noticed unexplained fatigue or discomfort in the right upper abdomen
-
Have had abnormal liver function tests in the past
-
Drink alcohol regularly and are concerned about liver health
-
Are concerned about your liver health for any reason
Your GP can arrange appropriate blood tests and imaging to assess liver health and identify any abnormalities requiring further investigation. Initial assessment will include fibrosis risk stratification using validated scores (such as FIB-4) to determine whether specialist referral or further testing is needed.
You should be referred to a specialist hepatologist if:
-
Your FIB-4 score or NAFLD Fibrosis Score is high or indeterminate
-
Your Enhanced Liver Fibrosis (ELF) test score is 10.51 or above
-
Liver elastography (FibroScan) suggests significant fibrosis
-
You have abnormal liver synthetic function (low albumin, prolonged clotting times)
-
Your platelet count is low or your AST is higher than your ALT
-
You have clinical features suggesting advanced liver disease
Seek urgent medical attention if you develop:
-
Yellowing of the skin or eyes (jaundice)
-
Persistent nausea and vomiting
-
Severe abdominal pain or swelling
-
Confusion or altered mental state
-
Dark urine combined with pale stools
-
Unexplained bruising or bleeding
-
Vomiting blood or passing black, tarry stools
These symptoms may indicate advanced liver disease or acute liver injury requiring immediate assessment.
Regular monitoring is advisable for anyone diagnosed with fatty liver disease or NASH. According to NICE guidance, adults with NAFLD and no advanced fibrosis should have repeat assessment for advanced fibrosis every three years (children and young people every two years). Those with NASH, significant fibrosis, or indeterminate risk scores need more frequent assessment—typically annually or six-monthly—often under specialist hepatology care.
Patients with cirrhosis require six-monthly ultrasound surveillance for hepatocellular carcinoma (with or without alpha-fetoprotein blood test, depending on local practice) and regular endoscopic assessment for oesophageal varices. Early engagement with healthcare services, adherence to lifestyle modifications, and appropriate monitoring optimise outcomes and reduce the risk of progression to advanced liver disease. If you have concerns about your liver health or have been diagnosed with fatty liver disease, discuss an appropriate monitoring plan with your GP or specialist.
Frequently Asked Questions
Can simple fatty liver turn into NASH over time?
Yes, approximately 10–20% of people with simple fatty liver will progress to NASH, though the exact trajectory is unpredictable. Factors associated with progression include older age, obesity, type 2 diabetes, and the presence of metabolic dysfunction, making lifestyle modification and regular monitoring essential.
How do doctors tell the difference between NASH and fatty liver without a biopsy?
Doctors use validated fibrosis risk scores such as FIB-4 (based on age, liver enzymes, and platelet count) and the Enhanced Liver Fibrosis (ELF) blood test to assess the likelihood of advanced disease. Liver elastography (FibroScan) can also measure liver stiffness, though liver biopsy remains the gold standard when precise diagnosis would change management.
What is the main difference between NASH and fatty liver disease?
The main difference is that NASH involves inflammation and liver cell damage (hepatocellular injury) in addition to fat accumulation, whilst simple fatty liver involves only fat deposits without significant inflammation. This inflammatory process in NASH can lead to progressive scarring (fibrosis) and potentially cirrhosis, whereas simple fatty liver rarely causes serious liver disease.
Is there any medication approved in the UK specifically for treating NASH?
No, there is currently no medication licensed specifically for NASH in the UK, though several agents are under investigation in clinical trials. Management focuses on lifestyle interventions (weight loss, diet, exercise), optimal control of metabolic conditions like diabetes and high cholesterol, and specialist monitoring for disease progression.
Can I reverse fatty liver or NASH if I lose weight?
Yes, weight loss is highly effective—losing 7–10% of body weight can significantly reduce liver fat, and weight loss exceeding 10% may resolve NASH and improve fibrosis in many patients. Lifestyle modifications including dietary changes and increased physical activity can often reverse simple fatty liver completely, making early intervention crucial.
How often should I have my liver checked if I have been diagnosed with fatty liver?
According to NICE guidance, adults with NAFLD and no advanced fibrosis should have repeat fibrosis assessment every three years, whilst children and young people require assessment every two years. Those with NASH, significant fibrosis, or indeterminate risk scores typically need more frequent monitoring—often annually or six-monthly under specialist hepatology care.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
